Airway administration of bisphosphate and dexamethasone inhibits SARS-CoV-2 variant infection by targeting alveolar macrophages

Signal Transduct Target Ther. 2022 Apr 6;7(1):116. doi: 10.1038/s41392-022-00977-1.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Drug Treatment*
  • Dexamethasone / pharmacology
  • Humans
  • Macrophages, Alveolar*
  • SARS-CoV-2

Substances

  • Dexamethasone

Supplementary concepts

  • SARS-CoV-2 variants